Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder Publisher

Nabizadeh F^{1, 2} ; Naser Moghadasi A³

Show Affiliations

1. Neuroscience Research Group, Universal Scientific Education and Research Network, Tehran, Iran
2. School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Current Journal of Neurology Published:2023

[No abstract available]

Style	Citing Format
MLA	Nabizadeh F, Naser Moghadasi A. "Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder." Current Journal of Neurology, vol. 22, no. 2, 2023, pp. 140-143.
APA	Nabizadeh F, Naser Moghadasi A (2023). Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder. Current Journal of Neurology, 22(2), 140-143.
Chicago	Nabizadeh F, Naser Moghadasi A. "Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder." Current Journal of Neurology 22, no. 2 (2023): 140-143.
Harvard	Nabizadeh F, Naser Moghadasi A (2023) 'Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder', Current Journal of Neurology, 22(2), pp. 140-143.
Vancouver	Nabizadeh F, Naser Moghadasi A. Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder. Current Journal of Neurology. 2023;22(2):140-143.
BibTex	@article{ author = {Nabizadeh F and Naser Moghadasi A}, title = {Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder}, journal = {Current Journal of Neurology}, volume = {22}, number = {2}, pages = {140-143}, year = {2023} }
RIS	TY - JOUR AU - Nabizadeh F AU - Naser Moghadasi A TI - Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder JO - Current Journal of Neurology VL - 22 IS - 2 SP - 140 EP - 143 PY - 2023 ER -